PPARG and type 2 diabetes mellitus: Although PPAR-γ synthetic agonists, e.g., pioglitazone, are clinically employed as drugs for the treatment of type 2 diabetes mellitus, these anti-diabetic drugs have anti-inflammatory properties making them promising candidates to treat inflammation in severe viral disease suggesting possible applications as modulators of host inflammatory and immune responses due to viral infections.